GSK completes buyout of Novartis from joint venture
07-06-2018
Novartis, FTC agreement paves way for $16bn buyout of GSK’s cancer unit
24-02-2015
in-focus / iStockphoto.com
Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
GSK, Pfizer, consumer health, joint venture, over the counter products, collaboration, research and development, Advil, Voltaren
